Hugo Biotech secures multimillion-yuan Pre-A2 round by TEB VC

Hugo Biotech has completed some ten million yuan in its Pre-A2 round of financing from TEB VC on June 29.

Hugo Biotech has completed some ten million yuan in its Pre-A2 round of financing from TEB VC on June 29.

Founded in 2017, Hugo Biotech is a developer of high-throughput microbial sequencing technology. The company focuses on microbial sequencing and microbial genome big data analysis that is used to determine the DNA and RNA sequences of pathogenic microorganisms in clinical samples.

Currently, Hugo Biotech has successfully developed an internationally leading cloud-based pathogenic microbial data analysis system, PACE (PAthogen Capture Engine).

Based on this engine, clinical samples such as cerebrospinal fluid, blood, alveolar lavage fluid, sterile body fluids, and tissues, can be processed for the DNA and RNA sequences of pathogenic microorganisms, enabling quick and accurate detection of microorganisms without the use of culturing processes and specific amplification.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/02/hugo-biotech-secures-multimillion-yuan-pre-a2-round-by-teb-vc/.

Leave a Reply

Please Login to Comment